PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.
Learn More →